FLASH Radiotherapy Maintains Systemic and Tissue Balance While Effectively Targeting Tumors - Scorecard - MDSpire

FLASH Radiotherapy Maintains Systemic and Tissue Balance While Effectively Targeting Tumors

  • By

  • Giulia Furini

  • Eduarda Mota da Silva

  • Alice Usai

  • Gaia Scabia

  • Claudia Kusmic

  • Francesco Faita

  • Andrea Cavalieri

  • Mariagrazia Celentano

  • Mario Costa

  • Filippo Rossi

  • Giulia Asero

  • Roberta Di Pietro

  • Emanuela Guerra

  • Stefano Lattanzio

  • Tonia Luca

  • Sergio Castorina

  • Roberto Cusano

  • Riccardo Berutti

  • Jessica Milia

  • Simone Capaccioli

  • Alessandra Gonnelli

  • Noemi Giannini

  • Fabiola Paiar

  • Saverio Cinti

  • Fabio Di Martino

  • Margherita Maffei

  • February 26, 2026

  • 0 min

Share

Clinical Scorecard: FLASH Radiotherapy Maintains Systemic and Tissue Balance While Effectively Targeting Tumors

At a Glance

CategoryDetail
ConditionMelanoma
Key MechanismsUltra-high-dose-rate (UHDR) radiotherapy (FLASH-RT) delivers radiation at dose rates ≥ 40 Gy/s, potentially sparing normal tissues while maintaining tumor control.
Target PopulationPatients with melanoma, particularly those undergoing radiotherapy.
Care SettingOncology, specifically in radiotherapy departments.

Key Highlights

  • FLASH-RT shows promise in reducing skin toxicity associated with conventional radiotherapy.
  • Approximately 90% of patients undergoing radiotherapy experience skin toxicity.
  • FLASH-RT has demonstrated comparable tumor control to conventional radiotherapy in preclinical models.
  • The FLASH effect may involve mechanisms such as oxygen depletion and altered DNA damage responses.
  • Clinical trials for FLASH-RT in melanoma are currently ongoing.

Guideline-Based Recommendations

Diagnosis

  • Utilize imaging and clinical evaluation for melanoma diagnosis.

Management

  • Consider FLASH-RT in multimodal treatment regimens for melanoma.

Monitoring & Follow-up

  • Monitor for skin toxicity and systemic effects post-radiotherapy.

Risks

  • Be aware of potential long-term complications such as fibrosis and necrosis.

Patient & Prescribing Data

Patients with advanced melanoma or those requiring palliative care.

FLASH-RT may offer a novel approach to minimize normal tissue damage while effectively targeting tumors.

Clinical Best Practices

  • Incorporate FLASH-RT in clinical trials to evaluate its efficacy and safety.
  • Assess systemic responses alongside local effects in irradiated patients.

References

Original Source(s)

FLASH Radiotherapy Maintains Systemic and Tissue Balance While Effectively Targeting Tumors

  • by Giulia Furini, Eduarda Mota da Silva, Alice Usai, Gaia Scabia, Claudia Kusmic, Francesco Faita, Andrea Cavalieri, Mariagrazia Celentano, Mario Costa, Filippo Rossi, Giulia Asero, Roberta Di Pietro, Emanuela Guerra, Stefano Lattanzio, Tonia Luca, Sergio Castorina, Roberto Cusano, Riccardo Berutti, Jessica Milia, Simone Capaccioli, Alessandra Gonnelli, Noemi Giannini, Fabiola Paiar, Saverio Cinti, Fabio Di Martino, Margherita Maffei

  • February 26, 2026

Related Content

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report